Outlook Therapeutics names Kevin Lundquist CFO, succeeding Lawrence Kenyon effective Sept. 1
Outlook Therapeutics said its CFO Lawrence A. Kenyon will leave the role effective September 1, 2026, and the Board appointed Kevin Lundquist as CFO, Treasurer and principal financial and accounting officer from the same date. Kenyon will stay on in a non-executive role through September 30, 2026, and will step down from the Board, which will shrink to eight directors. The company says the departure was not due to any disagreement over accounting, financial reporting or operations.
Key points
- Kevin Lundquist, 58, was CFO of CapsoVision Inc. from October 2024 to February 2026 and previously was CFO of Abzena Biologics from 2022 to 2023.
- Lundquist's base salary is $450,000, with a target bonus of 50% of salary and an option to buy 500,000 shares.
- Kenyon's separation agreement provides a lump sum of 12 months' base salary, $20,000 and his full 2026 target bonus, plus full option vesting and up to 12 months of COBRA benefits.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.